Late July to mid-September 2026 saw continued regulatory, clinical, and strategic momentum across nucleic acid therapeutic modalities, with notable clustering in rare neurological and neuromuscular disorders. On the regulatory front, the US FDA approved Ionis’ antisense oligonucleotide Zanvastro™ (zilganersen) for Alex...
June and July 2026 saw continued clinical, regulatory, and strategic momentum across nucleic acid therapeutic modalities, with notable clustering in antisense approaches to ALS and RNA-based approaches to obesity and cardiometabolic disease. On the regulatory front, Praxis Precision Medicines secured FDA Breakthrough T...
May and June 2026 saw significant clinical and regulatory momentum across nucleic acid therapeutic modalities and strategic activity included a multi-target ASO collaboration between Servier and n-Lorem Foundation in rare neurodevelopmental disorders, and WuXi AppTec’s announcement of a 17% increase in capital expendit...
Across April and May 2026, the nucleic acid therapeutics field saw broad regulatory momentum, continued clinical advancement, and significant manufacturing investment, with AI-driven drug discovery also advanced.
